Boston, November 2, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral therapies for the treatment of serious viral diseases, today announced its upcoming presentation at the American Society of Hepatology Annual Meeting 2023 Two posters presented at the 2016 Liver Conference. The Association for the Study of Liver Diseases (AASLD) meeting will be held November 10-14, 2023 in Boston, MA.
“We are very pleased to share the supporting data for bemnifosbuvir and Ruzasvir with the scientific and clinical communities, highlighting the potential of using these two compounds together as a novel treatment for hepatitis C virus (HCV),” said Dr. Jean-Pierre Sommadossi. Atea CEO and founder of Pharmaceuticals. “We are encouraged by the highly potent, genotype-wide antiviral activity of these compounds and the favorable drug interactions and safety profiles observed to date, which support their combined use. Despite the availability of treatment options for HCV, some problem. The large, underserved population of people with hepatitis C continues to grow dramatically due to the opioid crisis, injection drug use, and hepatitis C virus reinfection.”
Details of the speech are as follows:
Poster number: 1861-A
title: Bemnifosbuvir and Ruzasvir are potent HCV DAAs with good antiviral properties against the major HCV NS5A and NS5B RAV and support combined use
Date and time: Friday, November 10, 1:00 pm – 2:00 pm
Place: Hall A
Poster number: 1879-A
title: Lack of pharmacokinetic drug interaction between benifobuvir and ruzavir in healthy subjects
Date and time: Friday, November 10, 1:00 – 2:00 pm
Place: Hall A
About Bemnifosbuvir and Ruzasvir for the treatment of hepatitis C virus (HCV)
Atea is currently conducting a Phase 2 open-label study evaluating bemnifosbuvir in combination with ruzasvir (RZR) in patients with treatment-naïve HCV infection (without cirrhosis and/or compensated cirrhosis). This study was designed to evaluate the safety and efficacy of a pan-genotypic combination of once-daily benifobuvir 550 mg and RZR 180 mg for eight weeks. Approximately 280 treatment-naïve HCV-infected patients across all genotypes are expected to be recruited, including a lead-in cohort of 60 patients.
Bemnifosbuvir is a nucleotide polymerase inhibitor that has been shown to be approximately 10 times more active than sofosbuvir (SOF) in vitro A panel of laboratory strains and clinical isolates targeting HCV genotypes 1-5. in vitro Studies have shown that bemnifosbuvir is still fully active against SOF resistance-related strains (S282T), and its potency is 58 times higher than SOF. The pharmacokinetic (PK) profile of benifobuvir supports once-daily dosing for the treatment of HCV, and benifobuvir was well tolerated in healthy and HCV-infected subjects at doses up to 550 mg, sustained The duration is 8-12 weeks.
RZR is an oral NS5A inhibitor that has demonstrated potent pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. RZR has been treated in more than 1,200 HCV-infected patients for 12 weeks at daily doses up to 180 mg and demonstrated a favorable safety profile. RZR’s PK profile supports once-daily dosing.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address unmet medical needs in patients with severe viral infections. Leveraging the company’s in-depth understanding of antiviral drug development, nucleos
forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to historical facts should be deemed to be forward-looking statements, including, but not limited to, statements regarding: the date and time of the poster presentation, our expectations regarding the potential of our product candidates, including generally Benifobuvir combination product candidates, specifically the combination of Benifobuvir and RZR, and expectations for our pipeline, including trial design and development timelines. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause our current results, performance or achievements to differ from those expressed or implied by the forward-looking statements in any future There is a material difference in results, performance or achievements. Statement, including but not limited to, the uncertainties and costs associated with the clinical development of the combination of benifobuvir and RZR as a potential treatment for HCV and benifobuvir as a potential treatment for COVID-19. These and other important factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the SEC could cause actual results to differ from those indicated in the forward-looking statements. Results differ materially from the statements in this release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Although we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Contact information
Jonai Barnes
Senior Vice President, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
Will O’Connor
Rigorous investor relations
212-362-1200
will.oconnor@sternir.com
